Scheid pt 2.pdf
Acute Bacterial Rhinosinusitis in Adults:
Part II. Treatment
DEWEY C. SCHEID, M.D., M.P.H., and ROBERT. M. HAMM, PH.D. University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Although most cases of acute rhinosinusitis are caused by viruses, acute bacterial rhinosinusitis
is a fairly common complication. Even though most patients with acute rhinosinusitis recover
promptly without it, antibiotic therapy should be considered in patients with prolonged or
more severe symptoms. To avoid the emergence and spread of antibiotic-resistant bacteria, nar-
row-spectrum antibiotics such as amoxicillin should be used for 10 to 14 days. In patients with
mild disease who have beta-lactam allergy, trimethoprim/sulfamethoxazole or doxycycline are
options. Second-line antibiotics should be considered if the patient has moderate disease, recent
antibiotic use (past six weeks), or no response to treatment within 72 hours. Amoxicillin-clavu-
lanate potassium and fluoroquinolones have the best coverage for Haemophilus influenzae and
Streptococcus pneumoniae. In patients with beta-lactam hypersensitivity who have moderate
disease, a fluoroquinolone should be prescribed. The evidence supporting the use of ancillary
treatments is limited. Decongestants often are recommended, and there is some evidence to
support their use, although topical decongestants should not be used for more than three days
to avoid rebound congestion. Topical ipratropium and the sedating antihistamines have anticho-
linergic effects that may be beneficial, but there are no clinical studies supporting this possibility.
Nasal irrigation with hypertonic and normal saline has been beneficial in chronic sinusitis and
has no serious adverse effects. Nasal corticosteroids also may be beneficial in treating chronic
sinusitis. Mist, zinc salt lozenges, echinacea extract, and vitamin C have no proven benefit in
the treatment of acute bacterial rhinosinusitis. (Am Fam Physician 2004;70:1697-704,1711-12.
Copyright 2004 American Academy of Family Physicians.)
In this article, the evidence supporting
different treatments for acute bacterial
part one1 of this two-part article, clinical RESULTS OF CLINICAL TRIALS
criteria for evaluating ABRS are described.
There have been no randomized controlled
▲ Patient informa-
trials (RCTs) of antibiotic treatment for ABRS
A handout on sinus
using sinus aspirate cultures before and after
About two thirds of patients with ABRS treatment, although nonrandomized trials
authors of this article, is provided on page 1711.
improve without antibiotic treatment, have demonstrated bacteriologic cures. Five and most patients with viral upper respi-
RCTs and two meta-analyses have compared
See page 1621 for definitions of strength-of-
ratory infection (URI) improve within antibiotics, usually amoxicillin and trim-
seven days.2 Antibiotic therapy should be ethoprim-sulfamethoxazole (TMP-SMX;
reserved for patients who have Bactrim, Septra), with placebo, with clini-had symptoms for more than cal improvement as the outcome, which is
Antibiotic therapy should be
seven days and who present the more clinically relevant patient-oriented
reserved for use in patients
outcome.4,5 About 47 percent of patients
who have had symptoms
teria for ABRS (purulent nasal treated with antibiotics and 32 percent of the
for more than seven days
discharge, maxillary tooth or control group were cured at 10 to 14 days.
and who meet two or more
Eighty-one percent of patients treated with
clinical criteria for acute bac-
lateral], unilateral maxillary antibiotics and 66 percent of the control
group were cured or improved, meaning one
ing symptoms after initial patient benefited for every seven treated with
November 1, 2004
◆ Volume 70, Number 9
American Family Physician 1697
Downloaded from the American Family Physician
Web site at www.aafp.org/afp. Copyright 2004 American Academy of Family Physicians. For the private, noncommercial
use of one individual user of the Web site. All other rights reserved. Contact [email protected]
for copyright questions and/or permission requests.
Diagnosis and Management of Acute Bacterial Rhinosinusitis
in Immunocompetent Adults
Initial evaluation of upper respiratory symptoms: duration of
symptoms > 7 days and ≤ 4 weeks; positive findings (at least 2): • Purulent nasal discharge
• Maxillary tooth or facial pain (especially unilateral)
• Unilateral maxillary sinus tenderness
• Worsening symptoms after initial improvement
• Periorbital swelling• Severe facial or dental pain• Altered mental status• Diplopia
Recent (within six weeks) use of antibiotics?
Prevalence of resistant organisms > 30 percent?
Additional evaluation and treatment: • Extended antibiotic treatment 10 to 14 days (depending on the drug) • Further evaluation of underlying risk factors• Consider sinus imaging
Refractory subacute and/or recurrent sinusitis:• Individualize medical therapy• Consider sinus imaging• Consider opportunistic infections, immunodeficiency, structural abnormalities• Consider referral to allergist or otolaryngologist for evaluation
Algorithm for diagnosis and management of acute bacterial rhinosinusitis in immuno-
antibiotics. The treatment effect in these tri-
rates—generally above 85 percent. The use of
als may have been underestimated because fluoroquinolones for ABRS is relatively new. the lack of specificity of diagnosis diluted the Ciprofloxacin (Cipro) and cefuroxime had effect of treatment.
90 percent resolution rates when adminis-
tered to patients in a primary care setting.8 In
mentin), cephalosporins (cefuroxime [Cef-
an open-label RCT, levofloxacin (Levaquin)
tin] and cefixime [Suprax]), and macrolides and clarithromycin had 96 and 93 percent (azithromycin [Zithromax] and clarithromy-
cin [Biaxin]), have been studied extensively.6,7
All have demonstrated similar clinical success past seven years concluded that newer broad-
1698 American Family Physician
Volume 70, Number 9
◆ November 1, 2004
spectrum antibiotics are no more effective
Although lacking complete H. influenzae
than narrow-spectrum antibiotics.4,5,10,11 In coverage, amoxicillin is still a good choice most of these studies, amoxicillin was com-
for a first-line antibiotic in community-
pared with a cephalosporin, a fluoroquino-
lone, or a macrolide. The rapid emergence of with resistant organisms improve anyway,18 antibiotic-resistant organisms associated with and because it is well tolerated and inex-ABRS has made choosing an antibiotic more pensive (Table 1)
.13-16 Higher daily doses of difficult. Surveillance studies have shown amoxicillin (3 to 4 g per day) may be neces-an increasing prevalence of antibiotic-resis-
sary in areas with a high prevalence of peni-
tant Streptococcus pneumoniae
.12,13 Up to 25 cillin-resistant S. pneumoniae
. TMP-SMX percent of these bacteria are penicillin resis-
and doxycycline are alternatives for use in
tant, and 15 percent are penicillin interme-
patients who are allergic to beta lactams, but
diate. Resistance to macrolides, doxycycline they have limited coverage for H. influenzae
(Vibramycin), and TMP-SMX is common.12 and S. pneumoniae
, and failure rates of up The prevalence of beta-lactamase–producing to 25 percent are possible.16 Erythromycin, Haemophilus influenzae
is about 30 percent, second-generation cephalosporins with less and resistance to TMP-SMX is common.12 activity against H. influenzae
(e.g., cefa-Nearly all Mycobacterium catarrhalis
isolates clor [Ceclor], cefprozil [Cefzil], loracarbef produce beta-lactamase.
[Lorabid]), and tetracycline should not be used to treat ABRS.19
SELECTING AN ANTIBIOTIC
Although the cephalosporins (cefpodoxime
To integrate current antibiotic resistance [Vantin], cefuroxime, cefdinir [Omnicef], surveillance data into antibiotic recom-
ceftriaxone [Rocephin]) and amoxicillin/cla-
mendations, the Sinus and Allergy Health vulanate potassium also have been recom-Partnership (SAHP) used the Poole Thera-
mended for initial treatment,16 any benefit of
peutic Outcomes Model, a mathematical these agents as initial therapy must be bal-model that predicts clinical efficacy for each anced against their much higher cost and con-of the antibiotics commonly prescribed for cerns about increasing antibiotic resistance in ABRS (Table 1)
.13-16 The model incorporates the community. A retrospective cohort study assumptions about the probability of bacte-
of a pharmaceutical database of 29,000 adults
rial infection, pathogen distribution, sponta-
with ABRS showed equivalent success rates
neous resolution rates, and in vitro activity of with the use of older, inexpensive antibiot-antibiotics.15
ics at one half the cost.20 A cost-effectiveness
When choosing antibiotic therapy for analysis showed that even if more expensive
ABRS, physicians should consider recent agents were 23 percent more effective than antibiotic use, efficacy, and cost. The SAHP amoxicillin, using them empirically would guidelines classify patients with ABRS into be cost effective only if the prevalence of two groups to determine initial treatment: true bacterial sinusitis in treated patients was (1) those with mild symptoms who have not greater than 80 percent.21received antibiotics within six weeks and (2)
Second-line antibiotics should be consid-
those who have moderately severe disease or ered when the patient has moderate disease, have received antibiotics within six weeks.16 has used antibiotics in the past six weeks, Patients with moderate disease are considered or has no response to treatment within less likely to have spontaneous resolution and 72 hours. Amoxicillin-clavulanate potas-thus have a higher rate of treatment failure. sium and fluoroquinolones (gatifloxacin The guidelines offer no criteria for severity. [Tequin], levofloxacin, and moxifloxacin The categorization of moderate or mild sever-
ity is left to the physician’s clinical judgment, age for H. influenzae
and S. pneumoniae
. but an example was offered with earlier rec-
Other choices include intramuscular ceftri-
axone or combination therapies including
high-dose amoxicillin; clindamycin (Cleo-
November 1, 2004
◆ Volume 70, Number 9
American Family Physician 1699
TABLE 1Oral Antibiotics Used in the Treatment of Acute Bacterial Rhinosinusitis
Mild disease and no recent
Moderate disease or
recent antibiotic use
Amoxicil in-clavulanate (high 2,000 mg every 12 hours§
TMP-SMX = trimethoprim-sulfamethoxazole.
*—Clinical efficacy based on calculation from the Poole Therapeutic Outcomes Model.
15†—Estimated cost to the pharmacist based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2004. Cost to the patient will be higher, depending on prescription fil ing fee. Cost is for 10 days of therapy, unless stated otherwise.
‡—Any benefit of these agents as initial therapy must be balanced against their much higher cost and concerns about increasing antibiotic resistance.
§—Based on amoxicil in component.
|—Cost is for five days of therapy, including injection fee.
¶—Combination therapies include high-dose amoxicil in or clindamycin plus cefixime or high-dose amoxicil in or clindamycin plus rifampin.16
**—Provides coverage for
Streptococcus pneumoniae but has no activity against
Information from references 13 through 16.
1700 American Family Physician
Volume 70, Number 9
◆ November 1, 2004
cin) plus cefixime; or high-dose amoxicillin or clindamycin plus rifampin (Rifadin).16
In patients with a history of beta-lactam
Ancillary Treatment for Acute Bacterial Rhinosinusitis
allergies, the use of fluoroquinolones or combination therapy with clindamycin and
Likely to be effective
DURATION OF TREATMENT
Most clinical trials have used 10- to 14-day
courses of antibiotic therapy. Sinus puncture
in at least 95 percent of patients after a
10-day course of antibiotics.22 Results of one
study showed no differences in clinical or
radiographic improvement between patients
receiving three- or 10-day courses of TMP-
SMX.23 However, this study was conducted
before 1995, and microbial resistance pat-
terns have changed since then. More recently,
five-day treatment courses with azithromycin
and telithromycin (Ketek) were found to be
When a patient fails to respond to therapy,
No proven benefit
additional history, physical examination, cul-
tures, or imaging may be necessary. If a change
in antibiotic therapy is made, the limitations
in coverage of the initial antibiotic should be
considered. A switch to a fluoroquinolone is
recommended after failure of amoxicillin or
doxycycline.16 Combination therapy may be advantageous, particularly in patients previ-
*—Although topical decongestants are effective, use must be limited to three days
ously treated with cefdinir or macrolides.
to avoid rebound congestion.
†—Often combined with an oral decongestant.
‡—Dosage varies by drug.
Information from references 26 through 48.
The evidence supporting the use of ancil-lary treatment for ABRS is relatively weak (Table 2)
.26-48 Some studies show improve-
patients, but reduced mucosal blood flow
ment in symptoms, but no treatments have may increase inflammation.30 Topical decon-been shown to affect the duration of ill-
gestants should not be used longer than three
ness.26-28 Oral decongestants can be used until days to avoid rebound vasodilation.
symptoms resolve. In patients with stable
hypertension, decongestants have not been antihistamines for treatment of patients shown to seriously increase blood pressure.29 with ABRS. Even though histamine does Decongestants should be used with caution not play a role in this infectious condition in patients with ischemic heart disease, glau-
except, possibly, in patients who also have
a predisposing allergic rhinitis, these drugs
Although topical decongestants have been have some anti-inflammatory effects that
advocated in the past, their use is more con-
may be beneficial.31 However, the anticho-
troversial. Symptoms are improved in some linergic effects of first-generation antihista-
November 1, 2004
◆ Volume 70, Number 9
American Family Physician 1701
mines could impair clearance by thickening cal xylometazoline (Otrivin) for three days. mucus.31 Newer second-generation antihis-
Patients who received fluticasone showed
tamines have little or no anticholinergic more rapid improvement (6.0 versus effect and may have a role in treatment of 9.5 days) than patients who received placebo.
patients with allergy and chronic sinusitis,
Nasal saline spray, nasal irrigation, and
mist humidification have been recommended
The topical anticholinergic agent ipratro-
in the past to promote mucociliary clearance
pium bromide (Atrovent) has been used to by decreasing congestion, moistening the decrease rhinorrhea in patients with the nasal cavity, and removing crusty mucus.31 common cold,32 but there are no studies in Most trials have been small, many were not patients with ABRS. Theoretically, ipratro-
controlled, and methods varied, so evidence
pium may increase the viscosity of mucus supporting their use is only fair.27,28,38 Saline and impair its clearance, but this effect irrigation is safe, and there are no docu-appears to be less prominent with ipratro-
mented serious adverse effects.38 Hypertonic
Most studies of intranasal steroids in decreased medication use in patients with
patients with ABRS have not shown an effect chronic sinusitis.39,40 Saline sprays have been on clinical outcomes. These studies often shown to reduce symptoms of rhinitis,41 but were underpowered and included patients there are no studies in patients with ABRS. who had chronic sinusitis and nasal poly-
Controlled studies of mist use in URI have
posis, as well as ABRS.33-36 A recent RCT,37 not shown a benefit.42,43limited to patients with a history of pre-
Guaifenesin (Hytuss), a mucolytic agent,
vious recurrent or chronic sinusitis, com-
pared fluticasone (Flovent) with placebo ning secretions, but there is no evidence of in the treatment of patients with ABRS. clinical benefit. An RCT showed no effect on Both groups received cefuroxime and topi-
mucociliary clearance in healthy subjects.44 However, guaifenesin did reduce nasal con-gestion in an RCT of patients infected with
Indications for Referral in Patients
with Bacterial Rhinosinusitis
mend the use of vitamin C, zinc salt loz-
Findings of severe acute bacterial rhinosinusitis
enges, or echinacea in patients with ABRS.
Using the outcome of cold symptoms after
Periorbital cel ulitisIntracranial abscess
seven days, a meta-analysis of eight clini-
cal trials of zinc salt–lozenge treatment for
the common cold did not find a significant
Pott’s puffy tumor (infectious erosion of the
benefit (odds ratio, 0.50; 95 percent confi-
dence interval, 0.19 to 1.29).46 Several trials
of echinacea extract in the treatment of the
Treatment failure after extended course of
common cold reported a mild benefit, but
each trial had serious methodologic flaws. A
recent RCT of echinacea in college students
Nosocomial infectionsImmunocompromised host
Complications and Referral
Biopsy to rule out granulomatous disease,
Patients with complications or treatment fail-
ure after extended antibiotic therapy should
Evaluation for immunotherapy of al ergic rhinitis
be referred to an otolaryngologist (Table 3)
Information from references 6 and 48.
Patients who are referred to otolaryngologists usually are evaluated with nasal endoscopy
1702 American Family Physician
Volume 70, Number 9
◆ November 1, 2004
Strength of Recommendations
Key clinical recommendation
Amoxicil in for 10 to 14 days is a reasonable first-line agent.
In patients with mild disease who have beta-lactam hypersensitivity,
trimethoprim-sulfamethoxazole (Bactrim, Septra) or doxycycline (Vibramycin) are reasonable, cost-effective, first-line options.
In patients with moderate disease, recent antibiotic use, or lack of treatment C
response within 72 hours, amoxicil in-clavulanate potassium (Augmentin) or a fluoroquinolone should be prescribed.
Ancil ary treatments such as decongestants, topical anticholinergics,
guaifenesin (Hytuss), saline nasal irrigation, and nasal corticosteroids may
Mist, zinc salt lozenges, echinacea, and vitamin C have no proven benefit.
Patients with complications or treatment failure after extended antibiotic
therapy should be referred to an otolaryngologist. Patients with frequent recurrences of acute bacterial rhinosinusitis and inadequately control ed al ergic rhinitis should be referred to an al ergist for consideration of immunotherapy.
and a sinus computed tomographic scan. 7. Low DE, Desrosiers M, McSherry J, Garber G, Wil iams Patients with frequent recurrences of ABRS
JW Jr, Remy H, et al. A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ 1997;156(suppl
and inadequately controlled allergic rhinitis
should be referred to an allergist for consider-
8. Weis M, Hendrick K, Til otson G, Gravel e K. Multi-
center comparative trial of ciprofloxacin versus cefu-roxime axetil in the treatment of acute rhinosinusitis
Members of various medical faculties develop articles for
in a primary care setting. Rhinosinusitis Investigation
“Practical Therapeutics.” This article is one in a series
coordinated by the Department of Family and Preventive
9. Kahn JB, Riel y-Bauvin K, Demartin EL, et al. Multi-
Medicine at University of Oklahoma Health Sciences
center, open-label, randomized study to compare the
Center, Tulsa, Okla. Coordinator of the series is John
safety and efficacy of oral levofloxacin and Biaxin in the treatment of acute maxil ary sinusitis in adults.
Abstracts from the Proceedings of the 35th Annual
The authors indicate that they do not have any conflicts
Meeting of the IDSA, San Francisco, September 13-18, 1997. Abstract 578.
of interest. Sources of funding: none reported.
10. De Bock GH, Dekker FW, Stolk J, Springer MP, Kievit J,
van Houwelingen JC. Antimicrobial treatment in acute maxil ary sinusitis: a meta-analysis. J Clin Epidemiol
1. Scheid DC, Hamm RM. Acute bacterial rhinosinus-
11. De Ferranti SD, Ioannidis JP, Lau J, Anninger WV, Barza
itis in adults: part I. Evaluation. Am Fam Physician
M. Are amoxycil in and folate inhibitors as effective as
other antibiotics for acute sinusitis? A meta-analysis. BMJ 1998;317:632-7.
2. Axelsson A, Chidekel N, Grebelius N, Jensen C. Treat-
ment of acute maxil ary sinusitis. A comparison of four
12. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg
different methods. Acta Otolaryngol 1970;70:71-6.
RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respira-
3. Hickner JM, Bartlett JG, Besser RE, Gonzales R, Hoff-
tory tract infection to commonly used antimicrobial
man JR, Sande MA. Principles of appropriate antibiotic
agents. J Antimicrob Chemother 2003;52:229-46.
use for acute rhinosinusitis in adults: background. Ann Intern Med 2001;134:498-505.
13. Karlowsky JA, Draghi DC, Thornsberry C, Jones ME,
Critchley IA, Sahm DF. Antimicrobial susceptibilities of
4. Wil iams JW Jr, Aguilar C, Cornell J, Chiquette ED,
, Haemophilus influenzae
Dolor RJ, Makela M, et al. Antibiotics for acute maxil-
and Moraxel a catarrhalis
isolated in two successive
lary sinusitis. Cochrane Database Syst Rev 2004;(2):
respiratory seasons in the US. Int J Antimicrob Agents
5. Diagnosis and treatment of acute bacterial rhinosinus-
14. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Mea-
itis. Evid Rep Technol Assess (Summ) 1999;9:1-5.
suring the comparative efficacy of antibacterial agents
6. Poole MD. A focus on acute sinusitis in adults: changes
for acute otitis media: the “Pol yanna phenomenon.”
in disease management. Am J Med 1999;106:38S-47S.
November 1, 2004
◆ Volume 70, Number 9
American Family Physician 1703
15. Poole MD. A mathematical therapeutic outcomes model
32. Hayden FG, Diamond L, Wood PB, Korts DC, Wecker
for sinusitis. Otolaryngol Head Neck Surg 2004;130(1
MT. Effectiveness and safety of intranasal ipratropium
bromide in common colds. A randomized, double-blind,
16. Anon JB, Jacobs MR, Poole MD, Ambrose PG, Ben-
placebo-control ed trial. Ann Intern Med 1996;125:89-
ninger MS, Hadley JA, et al. Antimicrobial treatment
guidelines for acute bacterial rhinosinusitis. Otolaryn-
33. Krouse HA, Phung ND, Klaustermeyer WB. Intranasal
gol Head Neck Surg 2004;130(1 suppl):1-45.
beclomethasone in severe rhinosinusitis and nasal pol-
17. Antimicrobial treatment guidelines for acute bacterial
rhinosinusitis. Sinus and Al ergy Health Partnership.
34. Cuenant G, Stipon JP, Plante-Longchamp G, Baudoin C,
Otolaryngol Head Neck Surg 2000;123(1 pt 2):5-31.
Guerrier Y. Efficacy of endonasal neomycin-tixocortol
18. Gwaltney JM Jr, Sydnor A Jr, Sande MA. Etiology and
pivalate irrigation in the treatment of chronic al ergic
antimicrobial treatment of acute sinusitis. Ann Otol
and bacterial sinusitis. ORL J Otorhinolaryngol Relat
Rhinol Laryngol Suppl 1981;90(3 pt 3):68-71.
19. Gwaltney JM Jr, Jones JG, Kennedy DW. Medical man-
35. Qvarnberg Y, Kantola O, Salo J, Toivanen M, Valtonen
agement of sinusitis: educational goals and manage-
H, Vuori E. Influence of topical steroid treatment on
ment guidelines. The International Conference on Sinus
maxil ary sinusitis. Rhinology 1992;30:103-12.
Disease. Ann Otol Rhinol Laryngol Suppl 1995;167:22-
36. Meltzer EO, Orgel HA, Backhaus JW, Busse WW, Druce
HM, Metzger WJ, et al. Intranasal flunisolide spray as an
20. Picciril o JF, Mager DE, Frisse ME, Brophy RH, Goggin
adjunct to oral antibiotic therapy for sinusitis. J Al ergy
A. Impact of first-line vs second-line antibiotics for
the treatment of acute uncomplicated sinusitis. JAMA
37. Dolor RJ, Witsell DL, Hel kamp AS, Wil iams JW Jr,
Califf RM, Simel DL. Comparison of cefuroxime with
21. Balk EM, Zucker DR, Engels EA, Wong JB, Wil iams
or without intranasal fluticasone for the treatment of
JW Jr, Lau J. Strategies for diagnosing and treating
rhinosinusitis. The CAFFS Trial: a randomized control ed
suspected acute bacterial sinusitis: a cost-effectiveness
analysis. J Gen Intern Med 2001;16:701-11.
38. Papsin B, McTavish A. Saline nasal irrigation: its role as
22. Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A.
an adjunct treatment. Can Fam Physician 2003;49:168-
The microbial etiology and antimicrobial therapy of
adults with acute community-acquired sinusitis: a fif-
39. Rabago D, Zgierska A, Mundt M, Barrett B, Bobula J,
teen-year experience at the University of Virginia and
Maberry R. Efficacy of daily hypertonic saline nasal
review of other selected studies. J Al ergy Clin Immunol
irrigation among patients with sinusitis: a randomized
control ed trial. J Fam Pract 2002;51:1049-55.
23. Wil iams JW Jr, Hol eman DR Jr, Samsa GP, Simel DL.
40. Heatley DG, McConnell KE, Kil e TL, Leverson GE. Nasal
Randomized control ed trial of 3 vs 10 days of trime-
irrigation for the al eviation of sinonasal symptoms.
thoprim/sulfamethoxazole for acute maxil ary sinusitis.
Otolaryngol Head Neck Surg 2001;125:44-8.
41. Nuutinen J, Holopainen E, Haahtela T, Ruoppi P, Silvasti
24. Klapan I, Culig J, Oreskovic K, Matrapazovski M, Rados-
M. Balanced physiological saline in the treatment of
evic S. Azithromycin versus amoxicil in/clavulanate in
chronic rhinitis. Rhinology 1986;24:265-9.
the treatment of acute sinusitis. Am J Otolaryngol
42. Hendley JO, Abbott RD, Beasley PP, Gwaltney JM Jr.
Effect of inhalation of hot humidified air on experimen-
25. Roos K, Brunswig-Pitschner C, Kostrica R, Pietola M,
tal rhinovirus infection. JAMA 1994;271:1112-3.
Leroy B, Rangaraju M, et al. Efficacy and tolerability of
43. Forstall GJ, Macknin ML, Yen-Lieberman BR, Meden-
once-daily therapy with telithromycin for 5 or 10 days
drop SV. Effect of inhaling heated vapor on symptoms
for the treatment of acute maxil ary sinusitis. Chemo-
of the common cold. JAMA 1994;271:1109-11.
44. Sisson JH, Yonkers AJ, Waldman RH. Effects of guai-
26. Smith MB, Feldman W. Over-the-counter cold medica-
fenesin on nasal mucociliary clearance and ciliary beat
tions. A critical review of clinical trials between 1950
frequency in healthy volunteers. Chest 1995;107:747-
27. Zeiger RS. Prospects for ancil ary treatment of sinusitis
45. Wawrose SF, Tami TA, Amoils CP. The role of guaifen-
in the 1990s. J Al ergy Clin Immunol 1992;90(3 pt
esin in the treatment of sinonasal disease in patients
infected with the human immunodeficiency virus (HIV).
28. Mabry RL. Therapeutic agents in the medical man-
agement of sinusitis. Otolaryngol Clin North Am
46. Jackson JL, Peterson C, Lesho E. A meta-analysis of zinc
salts lozenges and the common cold. Arch Intern Med
29. Bravo EL. Phenylpropanolamine and other over-
the-counter vasoactive compounds. Hypertension
47. Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA,
D’Alessio D. Treatment of the common cold with unre-
30. Bende M, Fukami M, Arfors KE, Mark J, Stierna P,
fined echinacea. A randomized, double-blind, placebo-
Intaglietta M. Effect of oxymetazoline nose drops on
control ed trial. Ann Intern Med 2002;137:939-46.
acute sinusitis in the rabbit. Ann Otol Rhinol Laryngol
48. Spector SL, Bernstein IL, Li JT, Berger WE, Kaliner
MA, Schul er DE, et al. Parameters for the diagnosis
31. Benninger MS, Anon J, Mabry RL. The medical man-
and management of sinusitis. J Al ergy Clin Immunol
agement of rhinosinusitis. Otolaryngol Head Neck Surg
1704 American Family Physician
Volume 70, Number 9
◆ November 1, 2004
COLEGIO DE FARMACEUTICOS DE LA PROVINCIA DE SANTA FE 1ª Circunscripción DAP DEPARTAMENTO DE SIM Sistema de Información de ACTUALIZACION PROFESIONAL Medicamentos 26-06-09 GRIPE A (H1N1) MEDIDAS DE BIOSEGURIDAD Ante la alarma creada como consecuencia de la posibilidad de contagio de las personas por el virus de la influenza A (H1N1), existen numerosas consul
Safety Data Sheet Tetracycline 1. PRODUCT AND COMPANY IDENTIFICATION Product Name: Tetracycline Synonyms/Generic Names: 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12aoctahydro-3,6,10,12,12a- pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride SDS Number: 753.00 Product Use: For Educational Use Only Manufacturer: Columbus Chemical Industries, Inc.